



Case report

Cherubism. A case report

Paolo Cariati*, Fernando Monsalve Iglesias, José Fernández Solís, Alfredo Valencia Laseca, Ildefonso Martínez Lara

Hospital Universitario Virgen de las Nieves, Granada, Spain



ARTICLE INFO

Article history:

Received 4 April 2016

Accepted 3 June 2016

Available online 11 July 2016

Keywords:

Cherubism

Autosomal dominant inheritance

Benign fibro-osseous disorder

Self-limiting pathology

ABSTRACT

Cherubism is a rare disorder with autosomal dominant inheritance. It is classified as a benign fibro-osseous lesions and may involve either facial bone. Its typical dentofacial deformities are caused by mutations in the SH3BP2 gene. The protein encoded by SH3BP2 had a significant role in the regulation of osteoblasts and osteoclasts. Accordingly with the radiological findings, differential diagnoses includes fibrous dysplasia, giant cell granuloma, osteosarcoma, juvenile ossifying fibroma, fibrous osteoma, odontogenic cyst and hyperparathyroidism. The aim of the present report is twofold. First, we examine the importance of the proper management of these cases. Second, we describe this rare syndrome with the goal of proposing suitable treatments.

© 2016 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Querubismo. Discusión de un caso

RESUMEN

Palabras clave:

Querubismo

Herencia autosómica dominante

Enfermedad fibrosea benigna

Enfermedad autolimitante

El querubismo es una enfermedad rara. Presenta herencia autosómica dominante y es clasificada como una enfermedad fibrosea benigna. Las deformidades típicas de esta dolencia se deben a la alteración del gen SH3BP2 y pueden afectar a cualquier hueso del macizo facial. La proteína codificada por este gen es fundamental para el correcto funcionamiento de osteoblastos y osteoclastos. El diagnóstico diferencial debe incluir: displasia fibrosa, granuloma de células gigantes, osteosarcoma, fibroma osificante juvenil, fibroma osteoide e hiperparatiroidismo.

© 2016 Elsevier España, S.L.U. y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Todos los derechos reservados.

Introduction

Cherubism is an uncommon disease classified as a benign fibro-osseous pathology. It presents an autosomal dominant inheritance and normally appears during childhood.¹ Typical dentofacial deformities of this disorder are caused by mutations in SH3BP2 gene on chromosome 4 (SH3-domain binding protein 2).² The protein encoded by SH3BP2 is essential for bone metabolism. This results in formation of numerous cysts that affect facial bones. Specifically, lower jaw is often the most afflicted by pathology.³

Cherubism is self-limiting with regression after puberty. After age 30 lesions are often replaced with bone and radiologically not

visible.⁴ However, despite the relatively benign behavior, it might provoke major problems. Ocular complications are among the most serious and feared in these patients. In this light, orbital involvement does not occur after puberty but may still be present. Thus, patients with cherubism should be frequently examined by an ophthalmologist in order to perform a routine screening of the visual acuity.⁵

Case report

A 7 year old male visited the outpatient department of oral and maxillofacial surgery of our Hospital. Parents referred bilateral progressive swelling of jaw bones. Physical examination shows asymmetry of the face with gross chubby appearance. Deformities were more pronounced on jaw bone and on left side. In addition, patients presented upward gaze and bilateral submandibular

* Corresponding author.

E-mail address: paolocariati1@gmail.com (P. Cariati).




Fig. 1. 3D-reconstruction of patient lesions.

lymphadenopathy. In view of these findings, we decided to perform a panoramic radiograph and a head CT scan in order to guide the diagnosis. These tests showed several multilocular cysts in all four quadrants of jaws (Fig. 1). No significant alteration was observed with biochemical analysis of calcium metabolism. Finally, an incisional biopsy of cystic tissue was carried out. Histopathological examination evidenced many multinucleated giant cells. By correlating clinical, radiographic and histopathological features a final diagnosis of cherubism was made. After diagnosis, patient was referred to an ophthalmologist with the aim of beginning a routine screening of the visual acuity. No alteration was evidenced by eye examination. Against this backdrop, we decided to keep a conservative attitude.

Discussion

Cherubism results from replacement of bone with multilocular cysts due to osteoblasts and osteoclasts malfunctioning (Figs. 2 and 3, Supplementary Material). As already mentioned it represents a benign fibro-osseous pathology and it should be distinguished from central giant cell granuloma (CGCG), multiple giant-cell lesion syndrome, fibrous dysplasia, brown tumors and Ramon syndrome and hyperparathyroidism.⁶ Differential diagnosis is based on specific clinical, radiological and anatomo-pathological features.

Although the severity of pathology, no effective treatment exists. Therapy strategies include: (a) surgical treatment; (b) medical treatment.

In relation to surgery, the strategy of wait and see is the most commonly used in these patients (Table 1, Supplementary Material). Surgery before puberty is only recommended in case of serious deformity or severe psychological impact.⁷

In relation to medical treatment, there is no evidence for an effective medical treatment. Recently, Tacrolimus demonstrated great results in one case.⁸ Calcitonin might also be useful.⁹ These positive effects seem to be related with the inhibition of bone reabsorption. On the other hand, radiotherapy and adalimumab (TNF- α antagonist) have not proven utility.

Conclusion

This report contains three central points. First, a conservative attitude is recommended until after puberty. Second,

diagnosis of cherubism is based on the presence of specific clinical, radiological and histological characteristics. Notwithstanding, a genetic study might be useful to achieve a safe diagnosis in borderline cases. Indeed, treatment substantially differs across benign fibro-osseous tumors. Third, further study should be undertaken regarding the effect of medical treatment in this disorder.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Financial assistance

Authors not received financial assistance.

Authors' contributions

All authors participated in the creation of manuscript.

Conflict of interest

The authors declare that they have no competing interests.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.reuma.2016.06.002>.

References

1. Kozakiewicz M, Perczynska-Partyka W, Kobos J. Cherubism – clinical picture and treatment. *Oral Dis.* 2001;7:123–30.
2. Mario Pérez-Sayáns M, Barros-Angueira F, Suárez-Peña JM, García-García A. Variable expressivity familial cherubism: woman transmitting cherubism without suffering the disease. *Head Face Med.* 2013;9:33.
3. Hyckel P, Berndt A, Schleier P, Clement JH, Beens V, Peters H, et al. Cherubism – new hypotheses on pathogenesis and therapeutic consequences. *J Craniomaxillofac Surg.* 2005;33:61–8.
4. Mehrotra D, Kesarwani A, Nandlal. Cherubism: case report with review of literature. *J Maxillofac Oral Surg.* 2011;10:64–70.
5. Colombo F, Cursiefen C, Neukam FW, Holbach LM. Orbital involvement in cherubism. *Ophthalmology.* 2001;108:1884–8.
6. Silva GC, Gomez RS, Vieira TC, Silva EC. Cherubism: long-term follow-up of 2 patients in whom it regressed without treatment. *Br J Oral Maxillofac Surg.* 2007;45:567–70.
7. Jiao Y, Zhou M, Yang Y, Zhou J, Duan X. Cherubism misdiagnosed as giant cell tumor: a case report and review of literature. *Int J Clin Exp Med.* 2015; 8:4656–63.
8. Kadlub N, Vazquez MP, Galmiche L, L'Herminé AC, Dainese L, Ulinski T, et al. The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism. *J Bone Miner Res.* 2015;30:878–85.
9. Fernandes Gomes M, Ferraz de Brito Penna Forte L, Hiraoka CM, Augusto Claro F, Costa Armond M. Clinical and surgical management of an aggressive cherubism treated with autogenous bone graft and calcitonin. *ISRN Dent.* 2011; 2011:340960.